These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. Burchett KM; Yan Y; Ouellette MM PLoS One; 2014; 9(1):e85155. PubMed ID: 24409321 [TBL] [Abstract][Full Text] [Related]
23. Resistance to the short term antiproliferative activity of the G-quadruplex ligand 12459 is associated with telomerase overexpression and telomere capping alteration. Gomez D; Aouali N; Londoño-Vallejo A; Lacroix L; Mégnin-Chanet F; Lemarteleur T; Douarre C; Shin-ya K; Mailliet P; Trentesaux C; Morjani H; Mergny JL; Riou JF J Biol Chem; 2003 Dec; 278(50):50554-62. PubMed ID: 14525974 [TBL] [Abstract][Full Text] [Related]
24. Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors. Baerlocher GM; Rusbuldt J; Bussolari J; Huang F Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911605 [TBL] [Abstract][Full Text] [Related]
25. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532). El Daly H; Martens UM Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817 [TBL] [Abstract][Full Text] [Related]
26. Processive and distributive extension of human telomeres by telomerase under homeostatic and nonequilibrium conditions. Zhao Y; Abreu E; Kim J; Stadler G; Eskiocak U; Terns MP; Terns RM; Shay JW; Wright WE Mol Cell; 2011 May; 42(3):297-307. PubMed ID: 21549308 [TBL] [Abstract][Full Text] [Related]
27. Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies. Hills M; Lansdorp PM Ann N Y Acad Sci; 2009 Sep; 1176():178-90. PubMed ID: 19796246 [TBL] [Abstract][Full Text] [Related]
28. Telomerase reverse transcriptase expression protects transformed human cells against DNA-damaging agents, and increases tolerance to chromosomal instability. Fleisig HB; Hukezalie KR; Thompson CA; Au-Yeung TT; Ludlow AT; Zhao CR; Wong JM Oncogene; 2016 Jan; 35(2):218-27. PubMed ID: 25893297 [TBL] [Abstract][Full Text] [Related]
29. Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Relitti N; Saraswati AP; Federico S; Khan T; Brindisi M; Zisterer D; Brogi S; Gemma S; Butini S; Campiani G Curr Top Med Chem; 2020; 20(6):433-457. PubMed ID: 31894749 [TBL] [Abstract][Full Text] [Related]
30. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190 [TBL] [Abstract][Full Text] [Related]
31. Administration with telomeric DNA telomere-like oligonucleotides induces enhancement of telomerase activity and resistance against oxidative stress in telomere reverse transcriptase gene-transfected human fibroblasts. Watanabe S; Saitoh Y; Namba M; Miwa N Biomed Pharmacother; 2010 Oct; 64(8):565-71. PubMed ID: 20347571 [TBL] [Abstract][Full Text] [Related]
32. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT. Brachner A; Sasgary S; Pirker C; Rodgarkia C; Mikula M; Mikulits W; Bergmeister H; Setinek U; Wieser M; Chin SF; Caldas C; Micksche M; Cerni C; Berger W Cancer Res; 2006 Apr; 66(7):3584-92. PubMed ID: 16585183 [TBL] [Abstract][Full Text] [Related]
33. Effects of telomerase modulation in human hematopoietic progenitor cells. Zimmermann S; Glaser S; Ketteler R; Waller CF; Klingmüller U; Martens UM Stem Cells; 2004; 22(5):741-9. PubMed ID: 15342938 [TBL] [Abstract][Full Text] [Related]
34. Mild hyperoxia limits hTR levels, telomerase activity, and telomere length maintenance in hTERT-transduced bone marrow endothelial cells. Napier CE; Veas LA; Kan CY; Taylor LM; Yuan J; Wen VW; James A; O'Brien TA; Lock RB; MacKenzie KL Biochim Biophys Acta; 2010 Oct; 1803(10):1142-53. PubMed ID: 20619302 [TBL] [Abstract][Full Text] [Related]
36. Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies. Babizhayev MA; Yegorov YE J Biomed Mater Res A; 2015 Dec; 103(12):3993-4023. PubMed ID: 26034007 [TBL] [Abstract][Full Text] [Related]
37. Treating Cancer by Targeting Telomeres and Telomerase. Ivancich M; Schrank Z; Wojdyla L; Leviskas B; Kuckovic A; Sanjali A; Puri N Antioxidants (Basel); 2017 Feb; 6(1):. PubMed ID: 28218725 [TBL] [Abstract][Full Text] [Related]
38. Telomere maintenance by telomerase and by recombination can coexist in human cells. Cerone MA; Londono-Vallejo JA; Bacchetti S Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631 [TBL] [Abstract][Full Text] [Related]
39. Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. Wu X; Zhang J; Yang S; Kuang Z; Tan G; Yang G; Wei Q; Guo Z Oncotarget; 2017 Feb; 8(8):13600-13619. PubMed ID: 28099140 [TBL] [Abstract][Full Text] [Related]
40. DNA Methylation Profiling of hTERT Gene Alongside with the Telomere Performance in Gastric Adenocarcinoma. Vahidi S; Norollahi SE; Agah S; Samadani AA J Gastrointest Cancer; 2020 Sep; 51(3):788-799. PubMed ID: 32617831 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]